Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

Cisplatin Resistance Associated with PARP Hyperactivation

(2013) J. Michels et al.   CANCER RESEARCH

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation

(2013) Loris De Cecco et al.   PLoS One

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

(2012) M. Lemoine et al.   BLOOD

Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells

(2012) W. Fiskus et al.   CLINICAL CANCER RESEARCH

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors

(2012) Michele Cea et al.   CURRENT PHARMACEUTICAL DESIGN

Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells

(2012) Linda Marek et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation

(2011) Jessica ES Bohonowych et al.   BMC CANCER

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells

(2011) Christoph Wohlkoenig et al.   CANCER LETTERS

HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer

(2011) E. A. Stronach et al.   CANCER RESEARCH

HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia

(2011) Hao Geng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

(2011) N. Sunaga et al.   MOLECULAR CANCER THERAPEUTICS

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

(2011) Yen-Ying Ma et al.   Taiwanese Journal of Obstetrics & Gynecology

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

(2011) Ana-Maria Florea et al.   Cancers

c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589

(2010) John Kauh et al.   PLoS One

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

(2010) Julia M. Wagner et al.   Clinical Epigenetics

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Metal Complexes, their Cellular Targets and Potential for Cancer Therapy

(2009) Di Chen et al.   CURRENT PHARMACEUTICAL DESIGN

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA

The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines

(2009) Michael B Prystowsky et al.   JOURNAL OF PATHOLOGY

Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

(2008) Kei-ichi Ozaki et al.   CANCER SCIENCE

Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

(2008) Q. Zhou et al.   MOLECULAR CANCER RESEARCH